Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: ORP-101 in IBS-D
NCT04129619Phase 2Completed
- Sponsor
- OrphoMed, Inc.
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ORP-101 in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by OrphoMed, Inc. Primary endpoint: Percentage of Participants Who Are Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12. Started Nov 2019; status: completed.
02
Drugs
ORP-101
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT04129619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129619.